Meso Scale Discovery (MSD) for Biomarker Analysis in Advanced Therapeutics
Frequently Asked Questions
Why use MSD over a standard ELISA for cytokine analysis?
The Meso Scale Discovery platform utilizes electrochemiluminescence (ECL) detection, which provides a superior dynamic range, often spanning 6-7 logs. This sensitivity, combined with its inherent multiplexing capability, allows for the simultaneous quantification of up to 10 distinct analytes from a single, low-volume sample. This is a significant advantage over traditional ELISAs, which are typically limited to a single analyte per well and have a much narrower quantitative range.
How does the MSD platform handle complex biological matrices?
MSD assays demonstrate high tolerance for complex matrices such as cerebrospinal fluid (CSF), plasma, serum, and tissue homogenates. The ECL technology produces very low non-specific, or background signal, minimizing interference and enhancing the signal-to-noise ratio. This robustness allows for the accurate measurement of low-abundance biomarkers in preclinical and clinical samples where sample volume is often limited.
Are MSD assays developed at Franklin Biolabs suitable for regulatory submissions?
Yes. All bioanalytical assays, including those on the MSD platform, are developed and qualified or validated in a phase-appropriate manner. Our work is performed under GxP guidelines to generate high-integrity data packages suitable for inclusion in IND-enabling toxicology studies and subsequent regulatory filings.
Accurately quantifying pharmacodynamic responses is fundamental to de-risking the development of advanced therapeutics and complex biologics. Applying decades of experience and proven intelligence in bioanalysis accelerates therapeutic programs toward successful IND submissions.
The MSD platform provides a highly sensitive and robust method for quantifying biomarkers that help define a therapeutic’s mechanism of action and potential immunogenicity. The technology’s use of electrochemiluminescence allows for precise measurements across a wide concentration range, a capability often needed for characterizing concentration-response relationships.
Key applications of the MSD platform in therapeutic development include:
- Cytokine and Chemokine Profiling: Simultaneously measure panels of pro-inflammatory and anti-inflammatory cytokines to monitor immune activation.
- Phosphoprotein Analysis: Quantify changes in key signaling pathways to confirm on-target activity.
- Pharmacodynamic Biomarker Quantification: Measure target engagement and biological response in limited-volume samples from preclinical models or clinical trial participants.
- Potency and Functional Assays: Develop custom assays to assess the biological activity of a therapeutic product.
Beyond confirming on-target activity, developing genetic therapies requires navigating patient-specific biological factors. For instance, the high prevalence of pre-existing neutralizing antibodies against common AAV vectors can significantly impact patient eligibility and therapeutic efficacy (PMID: 19133809). In these scenarios, ultra-sensitive platforms like MSD become invaluable for developing robust immunogenicity assays to screen patient populations and monitor immune responses, ensuring a clearer path through clinical development.
At Franklin Biolabs, we design and execute tailored biomarker strategies that align with your program’s specific modality and target indication. Within our 100,000 square feet of specialized laboratory space, our immunology core develops custom multiplex panels or utilizes validated off-the-shelf kits to generate decision-driving data. This approach ensures that the bioanalytical component of your program is built on a foundation of precision and regulatory compliance.
Learn more about our comprehensive Bioanalytical Services and how we support programs from early discovery through clinical trials.
